Literature DB >> 8083974

Improved cell survival by the reduction of immediate-early gene expression in replication-defective mutants of herpes simplex virus type 1 but not by mutation of the virion host shutoff function.

P A Johnson1, M J Wang, T Friedmann.   

Abstract

Derivatives of herpes simplex virus type 1 (HSV-1) have elicited considerable interest as gene transfer vectors because of their ability to infect a wide range of cell types efficiently, including fully differentiated neurons. However, it has been found that infection of many types of cell with vectors derived from replication-defective mutants of HSV-1 is associated with cytopathic effects (CPE). We have previously shown that viral gene expression played an important role in the induction of CPE caused by an HSV-1 mutant deleted for the essential immediate-early gene 3 (IE 3) (P.A. Johnson, A. Miyanohara, F. Levine, T. Cahill, and T. Friedmann, J. Virol. 66:2952-2965, 1992). We have investigated which viral genes might be responsible for CPE by comparing the ability of each of the individual genes expressed by an IE 3 deletion mutant during a nonproductive infection to inhibit biochemical transformation after cotransfection of BHK or CV-1 cells with a selectable marker gene. Transfection of IE genes 1,2, and 4 individually all caused a marked inhibition of colony formation, while transfection of IE 5 and the large subunit of ribonucleotide reductase had little effect. These results suggested that it would be necessary to mutate or reduce the expression of nearly all HSV-1 IE genes to reduce virus-induced CPE. Therefore, we have used VP16 mutants, which are unable to transinduce IE gene expression (C. I. Ace, T. A. McKee, J. M. Ryan, J. M. Cameron, and C. M. Preston, J. Virol. 63:2260-2269, 1989), to derive two replication-defective strains: 14H delta 3, which is deleted for both copies of IE 3, and in 1850 delta 42, which has a deletion in the essential early gene UL42. The IE 3-VP16 double mutant, 14H delta 3, is significantly less toxic than a single IE 3 deletion mutant over a range of multiplicities of infection, as measured in a cell-killing assay, and has an enhanced ability to persist in infected cells in a biologically retrievable form. In contrast, the UL42-VP16 double mutant, in 1850 delta 42, showed reduced toxicity only at low multiplicities of infection. To test the role of the virion host shutoff function as an additional candidate to influence virus-induced CPE, we have introduced a large insertion mutation into the virion host shutoff gene of an IE 3 deletion mutant and the double mutant 14H delta 3.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 8083974      PMCID: PMC237056     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

1.  The regions important for the activator and repressor functions of herpes simplex virus type 1 alpha protein ICP27 map to the C-terminal half of the molecule.

Authors:  M A Hardwicke; P J Vaughan; R E Sekulovich; R O'Conner; R M Sandri-Goldin
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

2.  Immediate-early regulatory gene mutants define different stages in the establishment and reactivation of herpes simplex virus latency.

Authors:  D A Leib; D M Coen; C L Bogard; K A Hicks; D R Yager; D M Knipe; K L Tyler; P A Schaffer
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

3.  Construction and characterization of a herpes simplex virus type 1 mutant unable to transinduce immediate-early gene expression.

Authors:  C I Ace; T A McKee; J M Ryan; J M Cameron; C M Preston
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

4.  Control of mRNA stability by the virion host shutoff function of herpes simplex virus.

Authors:  A A Oroskar; G S Read
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

5.  Evidence of DNA: protein interactions that mediate HSV-1 immediate early gene activation by VP16.

Authors:  S J Triezenberg; K L LaMarco; S L McKnight
Journal:  Genes Dev       Date:  1988-06       Impact factor: 11.361

6.  Mutational analysis of the herpes simplex virus type 1 trans-inducing factor Vmw65.

Authors:  C I Ace; M A Dalrymple; F H Ramsay; V G Preston; C M Preston
Journal:  J Gen Virol       Date:  1988-10       Impact factor: 3.891

7.  Herpes simplex virus type 1 ICP27 deletion mutants exhibit altered patterns of transcription and are DNA deficient.

Authors:  A M McCarthy; L McMahan; P A Schaffer
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

8.  The herpes simplex virus type 1 alpha protein ICP27 can act as a trans-repressor or a trans-activator in combination with ICP4 and ICP0.

Authors:  R E Sekulovich; K Leary; R M Sandri-Goldin
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

9.  Herpes simplex virus type 1 ICP0 plays a critical role in the de novo synthesis of infectious virus following transfection of viral DNA.

Authors:  W Z Cai; P A Schaffer
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

10.  Direct combinatorial interaction between a herpes simplex virus regulatory protein and a cellular octamer-binding factor mediates specific induction of virus immediate-early gene expression.

Authors:  P O'Hare; C R Goding; A Haigh
Journal:  EMBO J       Date:  1988-12-20       Impact factor: 11.598

View more
  37 in total

1.  Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo.

Authors:  C E Lilley; F Groutsi; Z Han; J A Palmer; P N Anderson; D S Latchman; R S Coffin
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Perturbation of cell cycle progression and cellular gene expression as a function of herpes simplex virus ICP0.

Authors:  W E Hobbs; N A DeLuca
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

3.  Development and optimization of herpes simplex virus vectors for multiple long-term gene delivery to the peripheral nervous system.

Authors:  J A Palmer; R H Branston; C E Lilley; M J Robinson; F Groutsi; J Smith; D S Latchman; R S Coffin
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

4.  Specific destruction of kinetochore protein CENP-C and disruption of cell division by herpes simplex virus immediate-early protein Vmw110.

Authors:  R D Everett; W C Earnshaw; J Findlay; P Lomonte
Journal:  EMBO J       Date:  1999-03-15       Impact factor: 11.598

5.  Infection of human NT2 cells and differentiated NT-neurons with herpes simplex virus and replication-incompetent herpes simplex virus vectors.

Authors:  J P Weir
Journal:  J Neurovirol       Date:  2001-02       Impact factor: 2.643

6.  Truncation of the C-terminal acidic transcriptional activation domain of herpes simplex virus VP16 renders expression of the immediate-early genes almost entirely dependent on ICP0.

Authors:  K L Mossman; J R Smiley
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

7.  Deletion of the virion host shutoff protein (vhs) from herpes simplex virus (HSV) relieves the viral block to dendritic cell activation: potential of vhs- HSV vectors for dendritic cell-mediated immunotherapy.

Authors:  Laila Samady; Emanuela Costigliola; Luci MacCormac; Yvonne McGrath; Steve Cleverley; Caroline E Lilley; Jill Smith; David S Latchman; Benny Chain; Robert S Coffin
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

8.  Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.

Authors:  T Todo; R L Martuza; S D Rabkin; P A Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

Review 9.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

Review 10.  Herpes simplex virus virion host shutoff protein: immune evasion mediated by a viral RNase?

Authors:  James R Smiley
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.